Mirum Pharmaceuticals, Inc. 4

CFO Eric Bjerkholt sold 5,000 shares of Mirum Pharmaceuticals, Inc. common stock on July 6, 2026 for approximately $617,000 under a Rule 10b5-1 plan.

On July 6, 2026, Mirum Pharmaceuticals, Inc. Chief Financial Officer Eric Bjerkholt sold a total of 5,000 shares of the company’s common stock in four open-market transactions under a pre-established Rule 10b5-1 trading plan, at weighted average prices ranging from approximately $121.67 to $124.94 per share, for total proceeds of about $617,000. Following these sales, his direct ownership decreased from 44,057 shares to 42,181 shares of common stock, indicating a modest portfolio adjustment rather than a full-scale exit from his equity position.

Filing Facts

CIK

1759425

Ticker

MIRM

Form

4

Source Type

fda

Accession

0001197350-26-000008

Alert Tier

6